Low Hypoglycemia Risk (when used without insulin/sulfonylureas)
Back to Journals ClinicoEconomics and Outcomes Research Volume 18 Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective Authors Torre E , Di Matteo S, Martinotti C , Bruno GM , Cabrino A, Fogliati EL, Giusti A, Barbieri M, Bottaro LC, Colombo GL Received 10 December 2025 Accepted for publication 28 March 2026 Published 1 May 2026 Volume 2026:18 585328 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Samer Hamidi Enrico Torre, 1 Sergio Di Matteo, 2 Chiara Martinotti, 2 Giacomo Matteo Bruno, 3 Alessandro Cabrino, 2 Emma Lucia Fogliati, 2 Andrea Giusti, 4 Marco Barbieri, 5 Luigi Carlo Bottaro, 6 Giorgio Lorenzo Colombo 3 1 Diabetology and Metabolic Diseases Unit, ASL3 Genoa, Genoa, Italy
The results indicate that there is a minor delay of gastric emptying during the early postprandial phase for subjects when treated with semaglutide, compared with placebo, but there is no overall effect on gastric emptying over a 5-h postprandial period [13]
Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease
If you're ready to simplify your wellness routine, NuraPatch is worth a try: This release was published on openPR
Reduced oral intake : Appetite suppression and early satiety may inadvertently decrease both food and fluid consumption
